Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Hong Kong Pharma Digital Technology Holdings Ltd. ( (HKPD) ).
Hong Kong Pharma Digital Technology Holdings Limited held its Annual General Meeting on December 12, 2025, during which all nine proposals were successfully approved by shareholders. Key resolutions included the re-election of board members, reclassification and redistribution of share capital to Classes A and B shares, implementation of a reverse share split, name change to Cellyan Biotechnology Co., Ltd, and the adoption of an updated equity incentive plan. These developments signify strategic adjustments aimed at enhancing the company’s operational structure and competitiveness in the pharmaceutical e-commerce sector.
More about Hong Kong Pharma Digital Technology Holdings Ltd.
Hong Kong Pharma Digital Technology Holdings Limited operates in the OTC pharmaceutical industry, offering cross-border e-commerce supply chain services and procurement/distribution solutions in the Hong Kong market. The company facilitates access to overseas OTC pharmaceutical products for Mainland Chinese customers through its subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited.
Average Trading Volume: 181,608
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.99M
Find detailed analytics on HKPD stock on TipRanks’ Stock Analysis page.